A new study presented at the European Academy of Dermatology and Venereology meeting reveals that patients using GLP-1 receptor agonist medications for obesity and diabetes experience nail detachment and hair loss at significantly higher rates than non-users. Researchers found that 39.3% of GLP-1 users reported onycholysis—where the nail separates from the bed—compared to just 8.7% of control patients, though medical experts emphasize that these aesthetic side effects are generally temporary and should not prompt patients to stop effective treatment on their own initiative.
Study Findings on Nail Detachment and Onycholysis Rates
Users of GLP-1 receptor agonists faced a fourfold higher likelihood of experiencing nail disorders, MedPage Today reported. The prospective study evaluated 575 GLP-1 agonist users alongside a control group of 1,329 participants who had obesity or type 2 diabetes but did not take the medications.
Data showed that 39% of GLP-1 users reported nail detachment, known medically as onycholysis, compared with 9% of controls. Once a nail separates from the bed, it cannot be reattached and requires several months or over a year to regrow. Nail discoloration affected 46% of GLP-1 users compared to 17% in the control group, bringing the total number of users reporting at least one nail disorder to 66%.
Users report higher rates of hair loss and scalp redness
A companion study examining hair and scalp conditions among the same participants found that unusual hair shedding affected 50% of GLP-1 users, compared to 34% of non-users. Loss of hair volume was reported by 42% of medication users versus 19% of controls. Fox News noted that scalp redness occurred roughly three times as often in the treatment group.
While rapid weight loss is widely known to trigger temporary telogen effluvium hair shedding, study authors observed that hair loss among GLP-1 users typically came with itching, scaling, or redness. This suggests that what is happening on the scalp may go beyond the classical shedding seen after rapid weight loss and involve an inflammatory component.
Weighing Weight Loss Against Nutritional Deficiencies
Researchers analyzed whether rapid weight loss and resulting nutritional deficiencies accounted for the dermatological changes. In clinical trials, GLP-1 drugs have produced up to 22% weight loss, while real-world results typically range from 2% to 8% in a year.
Dr. Caroline Apovian, director of obesity medicine and weight management at Mass General Brigham, told WCVB that nail problems can connect to deficiencies in protein, iron, zinc, calcium, magnesium, and fat-soluble vitamins. Apovian emphasized that patients taking GLP-1 medications should focus on consuming a balanced, nutrient-rich diet and consider a multivitamin rather than simply reducing calorie intake.
When researchers adjusted statistical models for existing health conditions and nutritional gaps, the association between the drugs and nail detachment narrowed. In the most rigorous sensitivity analysis counting only new-onset symptoms starting after medication initiation, the statistical link disappeared largely because about half of users reported that their nail problems existed prior to treatment.
Consult doctors before stopping treatment for nail changes
What should patients do if they notice nail or hair changes while taking Ozempic or Mounjaro?
Medical experts advise patients to mention any hair shedding, scalp redness, or nail abnormalities to their doctor rather than discontinuing therapy on their own initiative.
Did the study prove that GLP-1 medications directly cause fingernails to fall off?
Co-investigator Charles Taïeb noted that while the findings show a clear association, not everything happening during treatment is necessarily caused by the drug itself, pointing out that many participants reported pre-existing nail issues.
Where were the study participants recruited from?
The research involved patients recruited across France, the United States, Brazil, and Mexico.
Related reading